Nothing Special   »   [go: up one dir, main page]

UY29250A1 - Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.- - Google Patents

Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.-

Info

Publication number
UY29250A1
UY29250A1 UY29250A UY29250A UY29250A1 UY 29250 A1 UY29250 A1 UY 29250A1 UY 29250 A UY29250 A UY 29250A UY 29250 A UY29250 A UY 29250A UY 29250 A1 UY29250 A1 UY 29250A1
Authority
UY
Uruguay
Prior art keywords
cytotoxic agents
modified
taxanes
understanding new
new taxanes
Prior art date
Application number
UY29250A
Other languages
English (en)
Inventor
Ravi V J Chari
Michael L Miller
Baloglu Erkan
Commercon Alain
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29250(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY29250A1 publication Critical patent/UY29250A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevos agentes citotóxicos y su utilización terapéutica. Más específicamente, la invención se refiere a nuevos agentes citotóxicos que comprenden taxanos y su utilización terapéutica. Estos nuevos agentes citotóxicos tienen utilización terapéutica como resultado de proporcionar los taxanos a una población celular específica de forma dirigida mediante enlace químico del taxano con el agente de unión a la célula.
UY29250A 2004-12-07 2005-12-07 Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.- UY29250A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04292899A EP1688415A1 (en) 2004-12-07 2004-12-07 Cytotoxic agents comprising new C-2 modified taxanes

Publications (1)

Publication Number Publication Date
UY29250A1 true UY29250A1 (es) 2006-06-30

Family

ID=34931584

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29250A UY29250A1 (es) 2004-12-07 2005-12-07 Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.-

Country Status (12)

Country Link
US (1) US7598290B2 (es)
EP (2) EP1688415A1 (es)
JP (1) JP2008523020A (es)
AR (1) AR051785A1 (es)
AU (1) AU2005313445A1 (es)
CA (1) CA2614574A1 (es)
DO (1) DOP2005000243A (es)
PA (2) PA8654201A1 (es)
PE (1) PE20061063A1 (es)
TW (1) TW200640893A (es)
UY (1) UY29250A1 (es)
WO (1) WO2006061259A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
AU2006247471A1 (en) * 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
MX338185B (es) 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
WO2008115404A1 (en) 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
LT3153504T (lt) 2010-12-09 2019-02-11 Immunogen, Inc. Įkrautų skersinių jungčių agentų gavimo būdas
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
CA2388063C (en) * 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
IT1317731B1 (it) * 2000-01-18 2003-07-15 Indena Spa Tassani semisintetici con attivita' antitumorale ed antiangiogenetica.
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
WO2004013093A2 (en) * 2002-08-02 2004-02-12 Immunogen, Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
CN1942459A (zh) * 2004-05-14 2007-04-04 免疫基因公司 浆果赤霉素ⅲ化合物的简易合成方法

Also Published As

Publication number Publication date
PA8654201A1 (es) 2006-07-03
EP1688415A1 (en) 2006-08-09
DOP2005000243A (es) 2006-11-30
PE20061063A1 (es) 2006-11-06
TW200640893A (en) 2006-12-01
AU2005313445A1 (en) 2006-06-15
WO2006061259A2 (en) 2006-06-15
CA2614574A1 (en) 2006-06-15
AR051785A1 (es) 2007-02-07
US20070270482A1 (en) 2007-11-22
US7598290B2 (en) 2009-10-06
PA8654601A1 (es) 2006-09-08
EP1819687A2 (en) 2007-08-22
WO2006061259A3 (en) 2007-01-11
JP2008523020A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
UY29249A1 (es) Agentes citotóxicos que comprenden taxanos nuevos
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
TW200740956A (en) Organic electroluminescent devices
CL2012001250A1 (es) Compuestos derivados de espirooxoindol, antagonista de la interaccion entre p53 y mdm2; composición farmacéutica que lo comprende; a un kit farmacéutico; uso en el tratamiento del cancer.
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
UY29250A1 (es) Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.-
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CO6351786A2 (es) Inkibidores de la cinasa map p38
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
SV2009003393A (es) Polipeptidos de factor vii modificaciones y usos de los mismos
NO20080068L (no) Topisk unguale formuleringer
CR8767A (es) Indazoles sustituidos, composiciones que los contienen, procedimiento de preparacion y su uso
GT201400043A (es) Imidazopiridazinas sustituidas con amino
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
UY29361A1 (es) Pirroles e imidazoles sustituídos, composiciones que los contienen, procedimiento de fabricación y utilización
AR114148A2 (es) Composición terapéutica saborizada basada en arcilla
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina
CR20110010A (es) Formulaciones que tienen una compatibilidad mejorada con sustratos no tejidos
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
EA201071412A1 (ru) Дронедарон для предотвращения кардиоверсии